scholarly journals Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propensity score matching analysis

2017 ◽  
Vol 13 (6) ◽  
pp. 4832-4836
Author(s):  
Gyeong Eun Min ◽  
Hanjong Ahn
Keyword(s):  
Prostate Cancer ◽  
Propensity Score ◽  
Metastatic Prostate Cancer ◽  
Progression Free Survival ◽  
Free Survival ◽  
Luteinizing Hormone Releasing Hormone ◽  
Propensity Score Matching Analysis ◽  
Psa Nadir ◽  
Maximal Androgen Blockade ◽  
Androgen Blockade

scholarly journals Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: a propensity score-based study

2021 ◽  
Author(s):  
Ning wang ◽  
Yangtian Ye ◽  
Minhua Deng ◽  
Diwei Zhao ◽  
Lijuan Jiang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Propensity Score ◽  
Metastatic Prostate Cancer ◽  
Newly Diagnosed ◽  
Clinical Value ◽  
Free Survival ◽  
Group A ◽  
Oncological Results ◽  
Psa Nadir ◽  
Group B

Abstract Background Several studies showed that androgen deprivation therapy (ADT) plus local treatment of prostate could improve metastatic prostate cancer (mPCa) patients’ survival. To date there are few studies analyzed the value of prostate cryoablation in mPCa. The objective of our analysis is to evaluate the oncological results and clinical value of prostate cryoablation combined with ADT compared with ADT alone in newly diagnosed mPCa patients. Methods Newly diagnosed mPCa patients undergoing cryoablation plus ADT (group A) between January 2011 and November 2018 were identified. Patients receiving ADT alone (group B) were selected from the same institutional prostate cancer database by propensity score matching based on clinical characteristics. Oncological results and clinical value in symptom control and primary lesion treatment were compared. Results Fifty-four patients were included in each group. Prostate cryoablation was well tolerated. The median follow-up time was 40 (27–53) and 39 (31–54) months in group A and group B, respectively. Patients in group A had a lower median prostate-specific antigen (PSA) nadir (0.025 ng/mL vs. 0.230 ng/mL, p = 0.001), longer median failure-free survival (FFS) (39 months vs. 21 months, p = 0.005), and median metastatic castration-resistant prostate cancer (mCRPC)-free survival (39 months vs. 21 months, p = 0.007). No difference in cancer-specific survival and overall survival was found between the two groups. Multivariate Cox analysis showed combination therapy reduced the risk of FFS by 45.8% (HR = 0.542 [95% CI 0.329–0.893]; p = 0.016). Patients in group A had better clinical relief of urinary symptoms (79.1 vs. 59.1%, p = 0.044) and required less treatment of primary lesions for symptomatic relief (13.0 vs. 31.5%, p = 0.021). Conclusions Prostate cryoablation plus ADT decreases PSA nadir, prolongs FFS and mCRPC-free survival, relieves urinary symptoms and reduces the need for treating primary lesions in newly diagnosed mPCa patients compared to ADT alone.

scholarly journals PD28-08 RADIOTHERAPY FOR PROSTATE IN MEN WITH METASTATIC PROSTATE CANCER: A PROPENSITY-SCORE MATCHING ANALYSIS

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Ken-ichi Tabata ◽  
Takefumi Satoh ◽  
Hideyasu Tsumura ◽  
Daisuke Ishii ◽  
Tetsuo Fujita ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Metastatic Prostate Cancer ◽  
Propensity Score Matching Analysis

scholarly journals Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer

2021 ◽  
Vol 16 (4) ◽  
Author(s):  
David Guy ◽  
Rachel Glicksman ◽  
Roger Buckley ◽  
Patrick Cheung ◽  
Hans Chung ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Radical Prostatectomy ◽  
Metastatic Prostate Cancer ◽  
Proportional Hazards ◽  
Progression Free Survival ◽  
Cox Proportional Hazards ◽  
Metastatic Progression ◽  
Free Survival ◽  
Cox Proportional Hazards Models

Introduction: Identifying the optimal management of unfavorable-risk (ProCaRS high intermediate-, high-, and very high-risk categories) non-metastatic prostate cancer is an important public health concern given the large burden of this disease. We compared the rate of metastatic progression-free survival among men diagnosed with unfavorable-risk non-metastatic prostate cancer who were initially treated with radiation therapy or radical prostatectomy. Methods: Information was obtained from medical records at two academic centers in Canada from 333 men diagnosed with unfavorable-risk non-metastatic prostate cancer between 2007 and 2012. Median followup was 90.4 months. Men were eligible for study if they received either primary radiation therapy (n=164) or radical prostatectomy (n=169), in addition to various adjuvant and salvage therapies when deemed clinically appropriate. Patients were matched on prognostic covariates using two matching techniques. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HR) and confidence intervals (CI) for metastatic progression-free survival between groups. Results: After matching, treatment groups were balanced on prognostic variables except for percent core positivity. Hazard ratios from all Cox proportional hazards models (i.e., before and after matching, and with and without multivariable adjustment) showed no difference in the rate of metastatic progression-free survival between groups (adjusted unmatched HR 1.16, 95% CI 0.63, 2.13, p=0.64). Conclusions: Metastatic progression-free survival did not differ between men diagnosed with unfavorable risk non-metastatic prostate cancer who were treated with either radiation therapy or radical prostatectomy.

Sign in / Sign up

Export Citation Format

Share Document